Background:
The global burden of atherosclerosis and its implication to cause coronary heart disease and ischemic cardiac problems is the most prevalent cause of morbidity and
hospitalization. In the US, there has been an increase in the number of patients with cardiac
problems in the last decade, and still remains the primary cause of death in Europe as well as in
the US.
Objectives:
Even though therapeutic interventions and early diagnosis the formation of the fatty
lesion and its subsequent steps are possible, the therapeutic management of the disease remains
questionable when clinical data is observed. There is still scope for proper target identification
and biomarker recognition, which can serve as a baseline to develop efficient pharmacological
agent and delivery systems so that the disease incidence and prevalence can be controlled. The
present article highlights the current pathophysiological state of the disease and emerging strategies that are applied to manage the disease.
Findings:
This article gives an insight into the limitations of various conventionally used therapeutic agents for disease treatment. The emerging strategies that could prove efficacious in disease treatment. This article also gives an insight into current discoveries in the field of cellular
and molecular biology, such as the genetic role in causing dyslipidemia and the role of immune
cells and the role of non-coding small RNA, which can set the future direction to develop therapeutics interventions for atherosclerosis.